275 related articles for article (PubMed ID: 34224330)
1. Modulating the host immune response to fight against COVID-19: Where are we in 2021?
Hertanto DM; Sutanto H; Wiratama BS; Wungu CDK
Virulence; 2021 Dec; 12(1):1732-1736. PubMed ID: 34224330
[No Abstract] [Full Text] [Related]
2. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis guided therapeutic management of COVID-19: an immunological perspective.
Kumar A; Prasoon P; Sekhawat PS; Pareek V; Faiq MA; Kumari C; Narayan RK; Kulandhasamy M; Kant K
Int Rev Immunol; 2021; 40(1-2):54-71. PubMed ID: 33111578
[TBL] [Abstract][Full Text] [Related]
4. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.
Shawki MA; Elsayed NS; Mantawy EM; Said RS
Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):395-409. PubMed ID: 34057871
[TBL] [Abstract][Full Text] [Related]
5. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
6. Repurposing Antimalarials to Tackle the COVID-19 Pandemic.
Krishna S; Augustin Y; Wang J; Xu C; Staines HM; Platteeuw H; Kamarulzaman A; Sall A; Kremsner P
Trends Parasitol; 2021 Jan; 37(1):8-11. PubMed ID: 33153922
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.
Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699
[TBL] [Abstract][Full Text] [Related]
8. An Impaired Inflammatory and Innate Immune Response in COVID-19.
Park SH
Mol Cells; 2021 Jun; 44(6):384-391. PubMed ID: 34098591
[TBL] [Abstract][Full Text] [Related]
9. How glycobiology can help us treat and beat the COVID-19 pandemic.
Lardone RD; Garay YC; Parodi P; de la Fuente S; Angeloni G; Bravo EO; Schmider AK; Irazoqui FJ
J Biol Chem; 2021; 296():100375. PubMed ID: 33548227
[TBL] [Abstract][Full Text] [Related]
10.
Khan FI; Hassan F; Lai D
Front Immunol; 2021; 12():794780. PubMed ID: 35095870
[TBL] [Abstract][Full Text] [Related]
11. The role and delicate balance of Host Immunity in Coronavirus Disease-19.
Vyas AK; Varma V; Garg G; Gupta P; Trehanpati N
Iran J Immunol; 2021 Mar; 18(1):1-12. PubMed ID: 33787510
[TBL] [Abstract][Full Text] [Related]
12. Host sphingolipids: Perspective immune adjuvant for controlling SARS-CoV-2 infection for managing COVID-19 disease.
Prakash H; Upadhyay D; Bandapalli OR; Jain A; Kleuser B
Prostaglandins Other Lipid Mediat; 2021 Feb; 152():106504. PubMed ID: 33147503
[TBL] [Abstract][Full Text] [Related]
13. Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment.
Martinez MA
Front Immunol; 2021; 12():635371. PubMed ID: 33777024
[No Abstract] [Full Text] [Related]
14. CD147 inhibitors as a treatment for melanoma: Promising agents against SARS-CoV-2 infection.
Pourani MR; Nekooghadam SM; Youssefian L; Vahidnezhad H; Abdollahimajd F
Dermatol Ther; 2020 Nov; 33(6):e14449. PubMed ID: 33098610
[No Abstract] [Full Text] [Related]
15. Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.
Pathak Y; Mishra A; Choudhir G; Kumar A; Tripathi V
Pharmacol Rep; 2021 Jun; 73(3):926-938. PubMed ID: 33970450
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 Updates: Monoclonal Antibodies for COVID-19.
Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286
[No Abstract] [Full Text] [Related]
17. Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective.
Perazzolo S; Zhu L; Lin W; Nguyen A; Ho RJY
J Pharm Sci; 2021 Mar; 110(3):1002-1017. PubMed ID: 33248057
[TBL] [Abstract][Full Text] [Related]
18. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
Goel B; Bhardwaj N; Tripathi N; Jain SK
Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
[TBL] [Abstract][Full Text] [Related]
19. Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19.
Aldea M; Michot JM; Danlos FX; Ribas A; Soria JC
Cancer Discov; 2021 Jun; 11(6):1336-1344. PubMed ID: 33846172
[TBL] [Abstract][Full Text] [Related]
20. Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine.
Dzobo K; Chiririwa H; Dandara C; Dzobo W
OMICS; 2021 Jan; 25(1):13-22. PubMed ID: 32857671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
